OM
WHWK

Opaleye Management’s Whitehawk Therapeutics WHWK Stock Holding History

Opaleye Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-252,046
Closed -$3.23M – 47
2022
Q4 		$3.23M Buy
+252,046
New +$3.29M 1.12% 28
2021
Q4 		– Sell
-45,020
Closed -$1.32M – 46
2021
Q3 		$1.32M Buy
+45,020
New +$1.37M 0.25% 42
2021
Q2 		– Sell
-66,667
Closed -$1.29M – 59
2021
Q1 		$1.29M Buy
+66,667
New +$1.53M 0.19% 52

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Opaleye Management's WHWK Position: Q1 2023 in Review

Opaleye Management sold out of Whitehawk Therapeutics (WHWK) in Q1 2023, closing a stake of 252,046 shares — an estimated $3.23M sold.

Opaleye Management first reported a position in WHWK in Q1 2021 and held it in 3 quarters. The position peaked at $3.23M in Q4 2022. 70 funds tracked by Wall St. Rank hold WHWK as of Q1 2023.

  • Opaleye Management reported no remaining Whitehawk Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Opaleye Management sold 252,046 Whitehawk Therapeutics shares in Q1 2023, an estimated $3.23M.
  • Opaleye Management first reported a position in Whitehawk Therapeutics in Q1 2021 and held it in 3 quarters.
  • Opaleye Management's Whitehawk Therapeutics position peaked at $3.23M in Q4 2022.
  • 70 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2023.

Based on Opaleye Management's 13F filing for Q1 2023, filed 15 May 2023.